paroxetine indications/contra

Stem definitionDrug idCAS RN
serotonin and/or norepinephrine reuptake inhibitors, fluoxetine derivatives 2068 61869-08-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • BRL 29060A
  • BRL-29060A
  • paroxetine hydrochloride hydrate
  • brisdelle
  • paroxetine
  • paxetil
  • paxil
  • paroxetine hydrochloride
  • paroxetine mesylate
  • paroxetine hydrochloride hemihydrate
  • paroxetine hydrochloride anhydrous
  • paroxetine mesilate
  • paroxetine HCl
A serotonin uptake inhibitor that is effective in the treatment of depression.
  • Molecular weight: 329.37
  • Formula: C19H20FNO3
  • CLOGP: 4.24
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 39.72
  • ALOGS: -4.59
  • ROTB: 4

Drug dosage:

DoseUnitRoute
20 mg O

Approvals:

DateAgencyCompanyOrphan
Dec. 29, 1992 FDA APOTEX TECHNOLOGIES

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Exposure during pregnancy 5468.54 45.68 1447 9389 26116 3348907
Drug withdrawal syndrome 4008.37 45.68 957 9879 10828 3364195
Atrial septal defect 3733.99 45.68 707 10129 2166 3372857
Suicidal ideation 3004.64 45.68 827 10009 16878 3358145
Completed suicide 2361.18 45.68 782 10054 30332 3344691
Anxiety 2344.13 45.68 826 10010 38803 3336220
Ventricular septal defect 2274.63 45.68 435 10401 1404 3373619
Foetal exposure during pregnancy 2086.72 45.68 606 10230 14945 3360078
Patent ductus arteriosus 2085.75 45.68 386 10450 981 3374042
Tremor 1744.52 45.68 609 10227 27535 3347488
Aggression 1723.68 45.68 488 10348 10897 3364126
Suicide attempt 1708.81 45.68 522 10314 15325 3359698
Cardiac murmur 1652.30 45.68 356 10480 2347 3372676
Serotonin syndrome 1616.39 45.68 398 10438 5025 3369998
Agitation 1507.84 45.68 500 10336 19206 3355817
Depression 1500.50 45.68 598 10238 39172 3335851
Dizziness 1488.98 45.68 721 10115 75791 3299232
Insomnia 1308.43 45.68 527 10309 35371 3339652
Hyperhidrosis 1278.64 45.68 463 10373 23147 3351876
Irritability 1269.23 45.68 384 10452 10832 3364191
Overdose 1148.89 45.68 473 10363 33505 3341518
Intentional self-injury 1093.30 45.68 289 10547 4896 3370127
Disturbance in attention 1077.95 45.68 315 10521 7833 3367190
Paraesthesia 1077.22 45.68 426 10410 27122 3347901
Panic attack 1051.05 45.68 279 10557 4805 3370218
Toxicity to various agents 1044.35 45.68 487 10349 46567 3328456
Confusional state 1022.41 45.68 450 10386 37548 3337475
Nausea 998.68 45.68 667 10169 128978 3246045
Heart disease congenital 994.11 45.68 196 10640 763 3374260
Nightmare 977.56 45.68 270 10566 5432 3369591

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC N06AB05 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Selective serotonin reuptake inhibitors
CHEBI has role CHEBI:35474 anxiolytic drug
CHEBI has role CHEBI:50949 serotonin uptake inhibitor
CHEBI has role CHEBI:35469 antidepressant
MeSH PA D000928 Antidepressive Agents
MeSH PA D018687 Antidepressive Agents, Second-Generation
MeSH PA D002491 Central Nervous System Agents
MeSH PA D065690 Cytochrome P-450 CYP2D6 Inhibitors
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D011619 Psychotropic Drugs
MeSH PA D018490 Serotonin Agents
MeSH PA D017367 Serotonin Uptake Inhibitors
FDA EPC N0000175696 Serotonin Reuptake Inhibitor

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Premenstrual dysphoric disorder indication 596004
Generalized anxiety disorder indication 21897009 DOID:14320
Social phobia indication 25501002 DOID:11257
Depressive disorder indication 35489007 DOID:2848
Posttraumatic stress disorder indication 47505003 DOID:2055
Obsessive-compulsive disorder indication 191736004 DOID:10933
Menopausal flushing indication 198436008
Major depressive disorder indication 370143000
Panic disorder indication 371631005 DOID:594
Suicidal thoughts contraindication 6471006
Bipolar disorder contraindication 13746004 DOID:3312
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Upper gastrointestinal hemorrhage contraindication 37372002
Syndrome of inappropriate vasopressin secretion contraindication 55004003 DOID:3401
Acute nephropathy contraindication 58574008
Blood coagulation disorder contraindication 64779008 DOID:1247
Hyponatremia contraindication 89627008
Seizure disorder contraindication 128613002 DOID:1826
Mania contraindication 231494001
Disease of liver contraindication 235856003 DOID:409
Pathological fracture contraindication 268029009
Akathisia contraindication 285145004
Pregnancy, function contraindication 289908002
Serotonin syndrome contraindication 371089000
Bipolar affective disorder, current episode depression off-label use 191627008 DOID:3312
Fibromyalgia off-label use 203082005 DOID:631

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.51 Basic

Orange Book patent data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 7.5MG BASE BRISDELLE SEBELA IRELAND LTD N204516 June 28, 2013 RX CAPSULE ORAL 8946251 Aug. 4, 2026 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
EQ 7.5MG BASE BRISDELLE SEBELA IRELAND LTD N204516 June 28, 2013 RX CAPSULE ORAL 9393237 Aug. 4, 2026 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
EQ 7.5MG BASE BRISDELLE SEBELA IRELAND LTD N204516 June 28, 2013 RX CAPSULE ORAL 8658663 April 6, 2029 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 10.40 CHEMBL CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel Ki 5.07 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 7.46 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 6.72 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 7.42 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 7.47 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 7.05 DRUG MATRIX
Cytochrome P450 2D6 Enzyme IC50 6 DRUG MATRIX
Cytochrome P450 1A2 Enzyme IC50 4.96 WOMBAT-PK
Sodium-dependent dopamine transporter Transporter Kd 6.31 WOMBAT-PK
D(3) dopamine receptor GPCR Ki 5.42 WOMBAT-PK
Sodium-dependent noradrenaline transporter Transporter Kd 7.40 WOMBAT-PK
Beta-1 adrenergic receptor GPCR Ki 5 WOMBAT-PK
5-hydroxytryptamine receptor 1A GPCR Kd 4.52 CHEMBL
P2X purinoceptor 4 Ion channel IC50 5.33 CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 5.65 DRUG MATRIX
Substance-P receptor GPCR IC50 6.05 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 10.30 CHEMBL
Transporter Transporter Ki 7.23 CHEMBL
Sodium-dependent dopamine transporter Transporter Ki 9.36 CHEMBL
Transporter Transporter Ki 7.48 CHEMBL
Adrenergic receptor alpha-1 GPCR Ki 5.27 CHEMBL
Sodium-dependent dopamine transporter Transporter Ki 7.01 CHEMBL
Adrenergic receptor alpha-2 GPCR Ki 5.20 CHEMBL
Quinolone resistance protein NorA Transporter IC50 5.15 CHEMBL
Sodium-dependent noradrenaline transporter Transporter Ki 7.70 CHEMBL

External reference:

scroll-->
IDSource
4790 IUPHAR_LIGAND_ID
C3651908 UMLSCUI
D02260 KEGG_DRUG
CHEMBL490 ChEMBL_ID
3I3T11UD2S UNII
78246-49-8 SECONDARY_CAS_RN
4327 INN_ID
DB00715 DRUGBANK_ID
4020815 VANDF
N0000148335 NDFRT
N0000006422 NDFRT
32937 RXNORM
d03157 MMSL
321963000 SNOMEDCT_US
372595009 SNOMEDCT_US
29631 MMSL
004016 NDDF
43815 PUBCHEM_CID
CHEMBL1708 ChEMBL_ID
CHEMBL1200609 ChEMBL_ID
CHEMBL1256912 ChEMBL_ID
D017374 MESH_DESCRIPTOR_UI
CHEBI:7936 CHEBI
8PR PDB_CHEM_ID

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Paroxetine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-2003 TABLET, FILM COATED, EXTENDED RELEASE 12.50 mg ORAL ANDA 14 sections
Paroxetine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-2004 TABLET, FILM COATED, EXTENDED RELEASE 25 mg ORAL ANDA 14 sections
Paroxetine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-2005 TABLET, FILM COATED, EXTENDED RELEASE 37.50 mg ORAL ANDA 14 sections
Paroxetine HUMAN PRESCRIPTION DRUG LABEL 1 0378-7001 TABLET, FILM COATED 10 mg ORAL ANDA 14 sections
Paroxetine HUMAN PRESCRIPTION DRUG LABEL 1 0378-7002 TABLET, FILM COATED 20 mg ORAL ANDA 14 sections
Paroxetine HUMAN PRESCRIPTION DRUG LABEL 1 0378-7003 TABLET, FILM COATED 30 mg ORAL ANDA 14 sections
Paroxetine HUMAN PRESCRIPTION DRUG LABEL 1 0378-7004 TABLET, FILM COATED 40 mg ORAL ANDA 14 sections
Paroxetine HUMAN PRESCRIPTION DRUG LABEL 1 0574-0279 CAPSULE 7.50 mg ORAL NDA 19 sections
Paroxetine HUMAN PRESCRIPTION DRUG LABEL 1 0615-5576 TABLET, FILM COATED 10 mg ORAL ANDA 13 sections
Paroxetine HUMAN PRESCRIPTION DRUG LABEL 1 0615-5577 TABLET, FILM COATED 20 mg ORAL ANDA 13 sections
Paroxetine HUMAN PRESCRIPTION DRUG LABEL 1 0615-5578 TABLET, FILM COATED 30 mg ORAL ANDA 13 sections
Paroxetine HUMAN PRESCRIPTION DRUG LABEL 1 0615-5579 TABLET, FILM COATED 40 mg ORAL ANDA 13 sections
Paroxetine HUMAN PRESCRIPTION DRUG LABEL 1 0615-7985 TABLET, FILM COATED 20 mg ORAL ANDA 15 sections
PAROXETINE HUMAN PRESCRIPTION DRUG LABEL 1 0904-5676 TABLET, FILM COATED 10 mg ORAL ANDA 14 sections
PAROXETINE HUMAN PRESCRIPTION DRUG LABEL 1 0904-5677 TABLET, FILM COATED 20 mg ORAL ANDA 14 sections
PAROXETINE HUMAN PRESCRIPTION DRUG LABEL 1 0904-5678 TABLET, FILM COATED 30 mg ORAL ANDA 14 sections
PAROXETINE HUMAN PRESCRIPTION DRUG LABEL 1 0904-5679 TABLET, FILM COATED 40 mg ORAL ANDA 14 sections
PAROXETINE HUMAN PRESCRIPTION DRUG LABEL 1 10544-433 TABLET, FILM COATED 20 mg ORAL ANDA 14 sections
PAROXETINE HUMAN PRESCRIPTION DRUG LABEL 1 10544-809 TABLET, FILM COATED 40 mg ORAL ANDA 14 sections
PAROXETINE HUMAN PRESCRIPTION DRUG LABEL 1 12634-248 TABLET, FILM COATED 20 mg ORAL ANDA 14 sections
Paroxetine HUMAN PRESCRIPTION DRUG LABEL 1 13107-154 TABLET, FILM COATED 10 mg ORAL ANDA 15 sections
Paroxetine HUMAN PRESCRIPTION DRUG LABEL 1 13107-155 TABLET, FILM COATED 20 mg ORAL ANDA 15 sections
Paroxetine HUMAN PRESCRIPTION DRUG LABEL 1 13107-156 TABLET, FILM COATED 30 mg ORAL ANDA 15 sections
Paroxetine HUMAN PRESCRIPTION DRUG LABEL 1 13107-157 TABLET, FILM COATED 40 mg ORAL ANDA 15 sections
PAROXETINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-181 TABLET, FILM COATED 20 mg ORAL ANDA 15 sections
PAROXETINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-322 TABLET, FILM COATED 10 mg ORAL ANDA 15 sections
PAXIL HUMAN PRESCRIPTION DRUG LABEL 1 16590-514 TABLET, FILM COATED, EXTENDED RELEASE 12.50 mg ORAL NDA 15 sections
Paroxetine HUMAN PRESCRIPTION DRUG LABEL 1 21695-101 TABLET, FILM COATED 10 mg ORAL ANDA 14 sections
Paroxetine HUMAN PRESCRIPTION DRUG LABEL 1 21695-102 TABLET, FILM COATED 20 mg ORAL ANDA 14 sections
Paroxetine HUMAN PRESCRIPTION DRUG LABEL 1 21695-103 TABLET, FILM COATED 30 mg ORAL ANDA 14 sections